Kathryn A Phillips

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7574701/publications.pdf

Version: 2024-02-01

129	4,939	94433	102487
papers	citations	37 h-index	66 g-index

129	129	129	5369
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Potential Role of Pharmacogenomics in Reducing Adverse Drug Reactions. JAMA - Journal of the American Medical Association, 2001, 286, 2270.	7.4	598
2	Strategies to Identify the Lynch Syndrome Among Patients With Colorectal Cancer. Annals of Internal Medicine, 2011, 155, 69.	3.9	303
3	Potential Savings from Substituting Generic Drugs for Brand-Name Drugs: Medical Expenditure Panel Survey, 1997â€“2000. Annals of Internal Medicine, 2005, 142, 891.	3.9	219
4	Measuring Preferences for Health Care Interventions Using Conjoint Analysis: An Application to HIV Testing. Health Services Research, 2002, 37, 1681-1705.	2.0	189
5	Genetic Test Availability And Spending: Where Are We Now? Where Are We Going?. Health Affairs, 2018, 37, 710-716.	5.2	166
6	Continuing Screening Mammography in Women Aged 70 to 79 Years. JAMA - Journal of the American Medical Association, 1999, 282, 2156.	7.4	164
7	Measuring What People Value: A Comparison of "Attitude" and "Preference" Surveys. Health Services Research, 2002, 37, 1659-1679.	2.0	141
8	Assessing the cost-effectiveness of pharmacogenomics. AAPS PharmSci, 2000, 2, 80-90.	1.3	133
9	Measuring Patient Preferences for Colorectal Cancer Screening Using a Choice-Format Survey. Value in Health, 2007, 10, 415-430.	0.3	128
10	Diagnostics and biomarker development: priming the pipeline. Nature Reviews Drug Discovery, 2006, 5, 463-469.	46.4	104
11	A systematic review of cost-effectiveness analyses of pharmacogenomic interventions. Pharmacogenomics, 2004, 5, 1139-1149.	1.3	101
12	Using the Coronary Artery Calcium Score to Guide Statin Therapy. Circulation: Cardiovascular Quality and Outcomes, 2014, 7, 276-284.	2.2	95
13	Health and Economic Benefits of Increased Î²-Blocker Use Following Myocardial Infarction. JAMA - Journal of the American Medical Association, 2000, 284, 2748.	7.4	94
14	The economic value of personalized medicine tests: what we know and what we need to know. Genetics in Medicine, 2014, 16, 251-257.	2.4	91
15	Measuring the value of pharmacogenomics. Nature Reviews Drug Discovery, 2005, 4, 500-509.	46.4	88
16	An experiment on simplifying conjoint analysis designs for measuring preferences. Health Economics (United Kingdom), 2003, 12, 1035-1047.	1.7	76
17	How do physician assessments of patient preferences for colorectal cancer screening tests differ from actual preferences? A comparison in Canada and the United States using a statedâ€choice survey. Health Economics (United Kingdom), 2009, 18, 1420-1439.	1.7	74
18	Clinical practice patterns and cost effectiveness of human epidermal growth receptor 2 testing strategies in breast cancer patients. Cancer, 2009, 115, 5166-5174.	4.1	64

#	Article	IF	Citations
19	The effect of risk factor reductions between 1981 and 1990 on coronary heart disease incidence, prevalence, mortality and cost. Journal of the American College of Cardiology, 2001, 38, 1012-1017.	2.8	57
20	Drug Withdrawals in the United States: A Systematic Review of the Evidence and Analysis of Trends. Current Drug Safety, 2007, 2, 177-185.	0.6	54
21	Genomic Sequencing: Assessing The Health Care System, Policy, And Big-Data Implications. Health Affairs, 2014, 33, 1246-1253.	5.2	53
22	Methodological Issues in Assessing the Economic Value of Next-Generation Sequencing Tests: Many Challenges and Not Enough Solutions. Value in Health, 2018, 21, 1033-1042.	0.3	52
23	Coverage Policy Development for Personalized Medicine: Private Payer Perspectives on Developing Policy for the 21-Gene Assay. Journal of Oncology Practice, 2010, 6, 238-242.	2.5	51
24	How does cost matter in health-care discrete-choice experiments?. Health Economics (United) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 542	1.7	50
25	The Effect of Area HMO Market Share on Cancer Screening. Health Services Research, 2004, 39, 1751-1772.	2.0	49
26	Making genomic medicine evidence-based and patient-centered: a structured review and landscape analysis of comparative effectiveness research. Genetics in Medicine, 2017, 19, 1-11.	2.4	49
27	Willingness to pay for poison control centers. Journal of Health Economics, 1997, 16, 343-357.	2.7	48
28	Cost-effectiveness analysis of genetic testing for familial long QT syndrome in symptomatic index cases. Heart Rhythm, 2005, 2, 1294-1300.	0.7	46
29	An introduction to cost-effectiveness and costâ€“benefit analysis of pharmacogenomics. Pharmacogenomics, 2003, 4, 231-239.	1.3	45
30	Closing the Evidence Gap in the Use of Emerging Testing Technologies in Clinical Practice. JAMA - Journal of the American Medical Association, 2008, 300, 2542.	7.4	44
31	Health Technology Assessment and Private Payers' Coverage of Personalized Medicine. Journal of Oncology Practice, 2011, 7, 18s-24s.	2.5	44
32	Are Gatekeeper Requirements Associated with Cancer Screening Utilization?. Health Services Research, 2004, 39, 153-178.	2.0	43
33	Payer coverage policies for multigene tests. Nature Biotechnology, 2017, 35, 614-617.	17.5	42
34	Perspectives of US private payers on insurance coverage for pediatric and prenatal exome sequencing: Results of a study from the Program in Prenatal and Pediatric Genomic Sequencing (P3EGS). Genetics in Medicine, 2020, 22, 283-291.	2.4	41
35	Potential Use of Home HIV Testing. New England Journal of Medicine, 1995, 332, 1308-1311.	27.0	39
36	Challenges of Coverage Policy Development for Next-Generation Tumor Sequencing Panels: Experts and Payers Weigh In. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 311-318.	4.9	39

#	Article	IF	Citations
37	Availability and funding of clinical genomic sequencing globally. BMJ Global Health, 2021, 6, e004415.	4.7	37
38	Genetic testing and pharmacogenomics: issues for determining the impact to healthcare delivery and costs. American Journal of Managed Care, 2004, 10, 425-32.	1.1	37
39	Eligibility criteria in private and public coverage policies for BRCA genetic testing and genetic counseling. Genetics in Medicine, 2011, 13, 1045-1050.	2.4	36
40	The cost-effectiveness of expanded HIV counselling and testing in primary care settings: a first look. Aids, 2000, 14, 2159-2169.	2.2	35
41	Payer Coverage for Hereditary Cancer Panels: Barriers, Opportunities, and Implications for the Precision Medicine Initiative. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 219-228.	4.9	35
42	Willingness to use instant home HIV tests. American Journal of Preventive Medicine, 2003, 24, 340-348.	3.0	32
43	Addressing Challenges of Economic Evaluation in Precision Medicine Using Dynamic Simulation Modeling. Value in Health, 2020, 23, 566-573.	0.3	32
44	Personalized Medicine and Oncology Practice Guidelines: A Case Study of Contemporary Biomarkers in Colorectal Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2011, 9, 13-25.	4.9	31
45	Private payer coverage policies for exome sequencing (ES) in pediatric patients: trends over time and analysis of evidence cited. Genetics in Medicine, 2019, 21, 152-160.	2.4	29
46	Use of Real-World Evidence in US Payer Coverage Decision-Making for Next-Generation Sequencingâ€“Based Tests: Challenges, Opportunities, and Potential Solutions. Value in Health, 2020, 23, 540-550.	0.3	27
47	Challenges to the translation of genomic information into clinical practice and health policy: Utilization, preferences and economic value. Current Opinion in Molecular Therapeutics, 2008, 10, 260-6.	2.8	26
48	Impact of the U.S. panel on cost-effectiveness in health and medicine. American Journal of Preventive Medicine, 2002, 22, 98-105.	3.0	25
49	The Intersection Of Biotechnology And Pharmacogenomics: Health Policy Implications. Health Affairs, 2006, 25, 1271-1280.	5.2	25
50	Short-term costs of integrating whole-genome sequencing into primary care and cardiology settings: a pilot randomized trial. Genetics in Medicine, 2018, 20, 1544-1553.	2.4	25
51	Expanding Use of Clinical Genome Sequencing and the Need for More Data on Implementation. JAMA - Journal of the American Medical Association, 2020, 324, 2029.	7.4	24
52	Economic evidence on identifying clinically actionable findings with whole-genome sequencing: a scoping review. Genetics in Medicine, 2016, 18, 111-116.	2.4	23
53	Availability and payer coverage of BRCA1/2 tests and gene panels. Nature Biotechnology, 2015, 33, 900-902.	17.5	22
54	Tradeoffs of Using Administrative Claims and Medical Records to Identify the Use of Personalized Medicine for Patients With Breast Cancer. Medical Care, 2011, 49, e1-e8.	2.4	21

#	Article	IF	Citations
55	What are people willing to pay for whole-genome sequencing information, and who decides what they receive?. Genetics in Medicine, 2016, 18, 1295-1302.	2.4	21
56	Evolving Payer Coverage Policies on Genomic Sequencing Tests. JAMA - Journal of the American Medical Association, 2018, 319, 2379.	7.4	21
57	A Standardized BCR-ABL Monitoring Test: Assessment of Potential Adoption Impacts In Healthcare In the United States. Blood, 2010, 116, 4754-4754.	1.4	21
58	HIV-1 Drug Resistance Genotyping. Pharmacoeconomics, 2000, 18, 425-433.	3.3	20
59	Variation in screening mammography and Papanicolaou smear by primary care physician specialty and gatekeeper plan (United States). Cancer Causes and Control, 2004, 15, 883-892.	1.8	20
60	Regulatory Perspectives on Pharmacogenomics: A Review of the Literature on Key Issues Faced by the United States Food and Drug Administration. Medical Care Research and Review, 2006, 63, 301-326.	2.1	20
61	Potential public sector cost-savings from over-the-counter access to oral contraceptives. Contraception, 2015, 91, 373-379.	1.5	20
62	EXAMINING EVIDENCE IN U.S. PAYER COVERAGE POLICIES FOR MULTI-GENE PANELS AND SEQUENCING TESTS. International Journal of Technology Assessment in Health Care, 2017, 33, 534-540.	0.5	20
63	Moving beyond the Typologies of Managed Care: The Example of Health Plan Predictors of Screening Mammography. Health Services Research, 2004, 39, 179-206.	2.0	19
64	Economic evaluation of targeted cancer interventions: Critical review and recommendations. Genetics in Medicine, 2011, 13, 853-860.	2.4	19
65	User characteristics and out-of-pocket expenditures for progestin-only versus combined oral contraceptives. Contraception, 2012, 86, 666-672.	1.5	19
66	Payer decision making for next-generation sequencingâ€“based genetic tests: insights from cell-free DNA prenatal screening. Genetics in Medicine, 2017, 19, 559-567.	2.4	19
67	From the Past to the Present: Insurer Coverage Frameworks for Next-Generation Tumor Sequencing. Value in Health, 2018, 21, 1062-1068.	0.3	19
68	Influence of Patient Preferences on the Cost-Effectiveness of Screening for Lynch Syndrome. Journal of Oncology Practice, 2012, 8, e24s-e30s.	2.5	18
69	â€œWhat Goes Around Comes Aroundâ€: Lessons Learned from Economic Evaluations of Personalized Medicine Applied to Digital Medicine. Value in Health, 2017, 20, 47-53.	0.3	18
70	Insurance coverage for genomic tests. Science, 2018, 360, 278-279.	12.6	18
71	Colorectal Cancer Screening. American Journal of Preventive Medicine, 2006, 30, 378-384.	3.0	17
72	Patient costs for medication abortion: Results from a study of five clinical practices. Women's Health Issues, 2006, 16, 4-13.	2.0	17

#	Article	IF	Citations
73	Is the ¨$1000 Genome" really $1000? Understanding the full benefits and costs of genomic sequencing. Technology and Health Care, 2015, 23, 373-379.	1.2	17
74	Decision Making on Medical Innovations in a Changing Health Care Environment: Insights from Accountable Care Organizations and Payers on Personalized Medicine and Other Technologies. Value in Health, 2017, 20, 40-46.	0.3	17
75	Emergence of Hybrid Models of Genetic Testing Beyond Direct-to-Consumer or Traditional Labs. JAMA - Journal of the American Medical Association, 2019, 321, 2403.	7.4	17
76	Women's out-of-pocket expenditures and dispensing patterns for oral contraceptive pills between 1996 and 2006. Contraception, 2011, 83, 528-536.	1.5	16
77	Consumer familiarity, perspectives and expected value of personalized medicine with a focus on applications in oncology. Personalized Medicine, 2015, 12, 13-22.	1.5	15
78	Genomic Testing and Therapies for Breast Cancer in Clinical Practice. Journal of Oncology Practice, 2011, 7, e1s-e7s.	2.5	14
79	Economic Perspectives on Personalized Health Care and Prevention. Forum for Health Economics and Policy, 2013, 16, S23-S52.	0.8	14
80	Private Payer and Medicare Coverage for Circulating Tumor DNA Testing: A Historical Analysis of Coverage Policies From 2015 to 2019. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 866-872.	4.9	14
81	Cost Analyses of Genomic Sequencing: Lessons Learned from the MedSeq Project. Value in Health, 2018, 21, 1054-1061.	0.3	13
82	Influence of payer coverage and outâ€ofâ€pocket costs on ordering of NGS panel tests for hereditary cancer in diverse settings. Journal of Genetic Counseling, 2022, 31, 130-139.	1.6	13
83	Provider practice models for and costs of delivering medication abortion â€" evidence from 11 US abortion care settings. Contraception, 2007, 75, 45-51.	1.5	12
84	Medicare formulary coverage for top-selling biologics. Nature Biotechnology, 2009, 27, 1082-1084.	17.5	12
85	Valuing personalized medicine: willingness to pay for genetic testing for colorectal cancer risk. Personalized Medicine, 2007, 4, 341-350.	1.5	11
86	Gene expression profile testing for breast cancer and the use of chemotherapy, serious adverse effects, and costs of care. Breast Cancer Research and Treatment, 2011, 130, 619-626.	2.5	11
87	Most Americans Do Not Believe That There Is An Association Between Health Care Prices And Quality Of Care. Health Affairs, 2016, 35, 647-653.	5.2	11
88	Complicated legacies: The human genome at 20. Science, 2021, 371, 564-569.	12.6	11
89	Speaking in Tongues: Integrating Economics and Psychology into Health and Mental Health Services Outcomes Research. Medical Care Review, 1992, 49, 191-231.	0.9	10
90	Capacity building for assessing new technologies: approaches to examining personalized medicine in practice. Personalized Medicine, 2010, 7, 427-439.	1.5	10

#	Article	IF	Citations
91	Assessing the Value of Next-Generation Sequencing Technologies: An Introduction. Value in Health, 2018, 21, 1031-1032.	0.3	9
92	Insights From a Temporal Assessment of Increases in US Private Payer Coverage of Tumor Sequencing From 2015 to 2019. Value in Health, 2020, 23, 551-558.	0.3	9
93	Selection Bias into Health Plans with Specific Characteristics: A Case Study of Endogeneity of Gatekeeper Requirements and Mammography Utilization. Health Services and Outcomes Research Methodology, 2004, 5, 103-118.	1.8	8
94	Angiotensin Receptor Blockers on the Formularies of Medicare Drug Plans. Journal of General Internal Medicine, 2007, 22, 1172-1175.	2.6	8
95	Value of Genetic Testing for Hereditary Colorectal Cancer in a Probability-Based US Online Sample. Medical Decision Making, 2015, 35, 734-744.	2.4	8
96	The price of whole-genome sequencing may be decreasing, but who will be sequenced?. Personalized Medicine, 2017, 14, 203-211.	1.5	7
97	A practical first step using needs assessment and a survey approach to implementing a clinical pharmacogenomics consult service. JACCP Journal of the American College of Clinical Pharmacy, 2019, 2, 214-221.	1.0	7
98	The Economics of Pharmacogenomics. Current Pharmacogenomics and Personalized Medicine: the International Journal for Expert Reviews in Pharmacogenomics, 2003, 1, 277-284.	0.3	7
99	Multicancer Screening Tests: Anticipating And Addressing Considerations For Payer Coverage And Patient Access. Health Affairs, 2022, 41, 383-389.	5.2	7
100	Initial development of an evidence base for personalized medicineâ€™s translation to clinical practice and health policy. Personalized Medicine, 2006, 3, 411-414.	1.5	6
101	Novel personalized medicine technology:UGT1A1testing for irinotecan as a case study. Personalized Medicine, 2006, 3, 415-419.	1.5	6
102	Bringing evidence to the debate on abortion coverage in health reform legislation: findings from a national survey in the United States. Contraception, 2010, 82, 129-130.	1.5	6
103	Key emerging themes for assessing the cost-effectiveness of reporting incidental findings. Genetics in Medicine, 2015, 17, 314-315.	2.4	6
104	Quantifying Downstream Healthcare Utilization in Studies of Genomic Testing. Value in Health, 2020, 23, 559-565.	0.3	6
105	Private payer coverage policies for ApoE-e4 genetic testing. Genetics in Medicine, 2021, 23, 614-620.	2.4	6
106	The Global Market for Next-Generation Sequencing Tests Continues Its Torrid Pace. The Journal of Precision Medicine, 2018, 4, .	0.0	6
107	US private payersâ€™ perspectives on insurance coverage for genome sequencing versus exome sequencing: A study by the Clinical Sequencing Evidence-Generating Research Consortium (CSER). Genetics in Medicine, 2022, 24, 238-244.	2.4	6
108	Assessments of the Value of New Interventions Should Include Health Equity Impact. Pharmacoeconomics, 2022, 40, 489-495.	3.3	5

#	Article	IF	Citations
109	Differences in US healthcare coverage policies inBRCAtesting and potential implications. Personalized Medicine, 2012, 9, 5-8.	1.5	4
110	Assessing the Value and Implications of Personalized/Precision Medicine and the â€œLessons Learnedâ€• for Emerging Technologies: An Introduction. Value in Health, 2017, 20, 30-31.	0.3	4
111	Methods for Moving the Evaluation of Precision Medicine Into Practice and Policy. Value in Health, 2020, 23, 527-528.	0.3	4
112	Informing and Educating the Electorate about AIDS. Medical Care Review, 1990, 47, 3-13.	0.9	3
113	Important step forward in HIV-testing technolgies. American Journal of Preventive Medicine, 2003, 25, 167.	3.0	3
114	New Medicare Coverage Policy for Next-Generation Tumor Sequencing: A Key Shift in Coverage Criteria With Broad Implications Beyond Medicare. JCO Precision Oncology, 2018, 2, 1-5.	3.0	3
115	Laboratory business models and practices: implications for availability and access to germline genetic testing. Genetics in Medicine, 2021, 23, 1681-1688.	2.4	3
116	Out-of-pocket expenditures for oral contraceptives and number of packs per purchase. Journal of the American Medical Women's Association, 2004, 59, 36-42.	0.3	3
117	Willingness to recommend a health plan: who is dissatisfied and what don't they like?. American Journal of Managed Care, 2004, 10, 393-400.	1.1	3
118	Innovation in personalized medicine: BiDilÂ®as a case study for integrating clinical and policy developments. Personalized Medicine, 2006, 3, 421-427.	1.5	2
119	Developing an Economic and Policy Research Agenda for Blood Biomarkers of Neurodegenerative Diseases. JAMA Health Forum, 2021, 2, e211428.	2.2	1
120	Generic Drug Savings. Annals of Internal Medicine, 2005, 143, 845.	3.9	1
121	Barriers to insurance coverage of next-generation tumor sequencing by U.S. payers.. Journal of Clinical Oncology, 2014, 32, 6545-6545.	1.6	1
122	Hereditary cancer panel testing challenges and solutions for the latinx community: costs, access, and variants. Journal of Community Genetics, 2021, , 1.	1.2	1
123	Keeping Pace With Health System Change. Health Affairs, 2000, 19, 277-279.	5.2	0
124	Insured Women and Payment for Elective Abortion. Women's Health Issues, 2008, 18, 347-350.	2.0	0
125	Reply to Clinical practice patterns and cost effectiveness of human epidermal growth receptor 2 testing strategies in breast cancer patients. Cancer, 2010, 116, 3981-3981.	4.1	0
126	Utilization of cardiac monitoring tests in women with nonmetastatic breast cancer treated with trastuzumab. Personalized Medicine, 2013, 10, 703-708.	1.5	0

#	Article	IF	Citations
127	Can precision medicine help achieve the goal of reducing care when the risks exceed the benefits?. Personalized Medicine, 2019, 16, 365-367.	1.5	0
128	Financing of germline testing: implications for availability and access. Molecular Genetics and Metabolism, 2021, 132, S330-S331.	1.1	0
129	Prescription drug dispensing limits and patterns. Managed Care Interface, 2005, 18, 41-6.	0.2	0